JP2022554019A5 - - Google Patents

Info

Publication number
JP2022554019A5
JP2022554019A5 JP2022525889A JP2022525889A JP2022554019A5 JP 2022554019 A5 JP2022554019 A5 JP 2022554019A5 JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022554019 A5 JP2022554019 A5 JP 2022554019A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
free base
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022525889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059287 external-priority patent/WO2021092292A1/en
Publication of JP2022554019A publication Critical patent/JP2022554019A/ja
Publication of JP2022554019A5 publication Critical patent/JP2022554019A5/ja
Withdrawn legal-status Critical Current

Links

JP2022525889A 2019-11-08 2020-11-06 補体成分C5a受容体の遊離塩基結晶形態 Withdrawn JP2022554019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932652P 2019-11-08 2019-11-08
US62/932,652 2019-11-08
PCT/US2020/059287 WO2021092292A1 (en) 2019-11-08 2020-11-06 FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR

Publications (2)

Publication Number Publication Date
JP2022554019A JP2022554019A (ja) 2022-12-27
JP2022554019A5 true JP2022554019A5 (cg-RX-API-DMAC7.html) 2023-11-09

Family

ID=75846182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525889A Withdrawn JP2022554019A (ja) 2019-11-08 2020-11-06 補体成分C5a受容体の遊離塩基結晶形態

Country Status (13)

Country Link
US (3) US11026935B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022554019A (cg-RX-API-DMAC7.html)
KR (1) KR20220098179A (cg-RX-API-DMAC7.html)
CN (1) CN114641289A (cg-RX-API-DMAC7.html)
AU (1) AU2020378061A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007488A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155596A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001173A1 (cg-RX-API-DMAC7.html)
IL (1) IL292317A (cg-RX-API-DMAC7.html)
MX (1) MX2022005403A (cg-RX-API-DMAC7.html)
WO (1) WO2021092292A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305622B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380367B2 (en) 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
US20260027049A1 (en) 2024-07-23 2026-01-29 Amgen Inc. Avacopan formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
JP5819730B2 (ja) * 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト製造における方法及び中間体
AU2020380367B2 (en) * 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2023501789A5 (cg-RX-API-DMAC7.html)
TWI344957B (en) Chemical process and intermediates
US12534495B2 (en) Compositions and methods for treating CNS disorders
JP2000500154A (ja) モルホリン誘導体及び治療薬としてのそれらの使用
JP2851480B2 (ja) 結晶オキサチオラン誘導体
JP2023116503A5 (cg-RX-API-DMAC7.html)
JP2023120208A5 (cg-RX-API-DMAC7.html)
JP2021181446A5 (cg-RX-API-DMAC7.html)
JP2023519891A5 (cg-RX-API-DMAC7.html)
EA011164B1 (ru) Производные пиримидина для профилактики вич-инфекции
JP2021063129A5 (cg-RX-API-DMAC7.html)
US20210308149A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2008508885A5 (cg-RX-API-DMAC7.html)
JP2001507023A (ja) トリアゾロ[4,5−d]ピリミジニル誘導体および医薬としてのその使用
JP2023139178A (ja) 癌の組合せ治療
TW202430149A (zh) N,n-二甲基色胺之結晶形式及其使用方法
JP2010534669A5 (cg-RX-API-DMAC7.html)
US20130345418A1 (en) Process for purification of aprepitant
TWI399375B (zh) 嗎啉化合物之鹽
Edrees Relapsing polychondritis: a description of a case and review article
CN102131803A (zh) (1r,2s,3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1,2,3,4-四醇的固体形式及其使用方法
JP2024520897A5 (cg-RX-API-DMAC7.html)
PT1896439E (pt) Base cristalina de escitalopram e comprimidos orodispersíveis compreendendo base de escitalopram
RU2012136921A (ru) Твердые формы, содержащие производные циклопропиламида
JP2022502516A5 (cg-RX-API-DMAC7.html)